Open AccessNanomedicine for SARS-CoV-2: Therapeutic and Prophylactic Approach in Immunocompromised Individuals
Author(s) -
Basma H. Marghani
Publication year - 2021
Publication title -
journal of human physiology
Language(s) - English
Resource type - Journals
ISSN - 2661-3859
DOI - 10.30564/jhp.v3i2.3437
Subject(s) - medicine , immune system , vaccination , viral pneumonia , adjuvant , disease , nanomedicine , immunology , nanocarriers , pneumonia , intensive care medicine , infectious disease (medical specialty) , drug , covid-19 , pharmacology , materials science , nanoparticle , nanotechnology
SARS-CoV-2 is a novel coronavirus that first appeared in Wuhan, China in December 2019 and then spread all over the world, causing a global respiratory epidemic COVID-19 illness. Certain health conditions can increase your exposure to COVID-19, such as chronic obstructive lung disease, high blood pressure, cardiovascular disease, and diabetes. The immune system of the host is severely compromised in the event of a respiratory viral infection. Immunocompromised patients have a more difficult time avoiding respiratory viral infections, making them more vulnerable to COVID-19 pneumonia and increasing the death rate to 19%. The ability of SARS-CoV-2 to damage the host cell by modifying its own DNA or RNA and proliferating inside the host cell, with antiviral treatments and prophylactic vaccinations being tested. In recent years, numerous innovative technologies have been examined to diagnose, prevent and treat viral infections. Nano technology opens the way to distinguish the living cell mechanisms and develop new technologies that make it possible to diagnose and cure various viral infections in the early stage. The therapeutic and preventative approaches of nanomedicine are essential factors for curing SARS-CoV-2. The delivery of antiviral drugs based on nanocarrier, changes in pharmacokinetic/pharmacodynamic properties, leading in dose reduction, reductions in toxicity, increased bioavailability, and the prevention of the virus. The overall efficiency and safety of vaccinated adjuvant vaccine nanoparticles (VANs) helps enhance the immune response of older, immunocompromised persons with the greatest death rate of SARS-CoV-2. The review focuses on recent advancements in nanomedicine treatments and prevention strategies for SARS-CoV-2.